X. Henry Hu

Treating early versus treating mild: timing of migraine prescription medications among patients with diagnosed migraine.

Introduction.—Although research suggests that early treatment of migraine headache when the pain is mild results in better outcomes for patients, many patients delay taking their acute‐migraine medication until their headaches are moderate or severe. Understanding when and why patients use their migraine medications is an important first step to improve migraine management.

Treatment of migraine with rizatriptan: when to take the medication.

Objective.—To assess, in the setting of routine clinical practice, rizatriptans effectiveness in treating acute migraine at its onset versus in a later phase of the attack.

Can Migraineurs Accurately Identify Their Headaches as “Migraine” at Attack Onset?

Background.—While treating migraine early when the headache is mild is believed to link to improved treatment outcomes, it is not clear whether patients can correctly self‐identify a headache as a migraine at onset in real‐world settings.

Reliability and validity of the migraine therapy assessment questionnaire.

Objective.—To determine the reliability and validity of the Migraine Therapy Assessment Questionnaire (MTAQ).

Productivity cost benefit to employers of treating migraine with rizatriptan: A specific worksite analysis and model

Employers in the United States might not be aware of the productivity costs of migraine or the extent to which those costs can be reduced by optimal treatment. An economic model was developed to enable employers to estimate the productivity costs of migraine to their company and the savings that will accrue if those patients who suffer from migraine are treated with rizatriptan. Analyses were run for both a major financial services corporation and a representative U.S. company. The major financial services corporation, with 87,821 employees, is projected to lose 538 person-years annually, at an estimated cost of

Acute Migraine Treatment With Oral Triptans and NSAIDs in a Managed Care Population

23.8 million. A representative U.S. company with 10,000 employees is projected to lose 46.0 person-years of productive effort annually as a result of migraine, valued at approximately

Does early migraine treatment shorten time to headache peak and reduce its severity

1.94 million. The value of the annual work loss avoided if migraine is treated with rizatriptan is projected at

Predictability of Future Attacks by Migraineurs: A Prospective Observational Study

10.3 million for the financial services corporation and

Real-world experiences in migraine therapy with rizatriptan.

841,000 for the representative U.S. company. There is a substantial productivity cost burden of migraine from a U.S. employer perspective. These productivity costs can be reduced significantly by treating migraine headaches with rizatriptan.

Burden of Migraine in the United States Disability and Economic Costs

Objective.— To describe the use of oral triptans with or without nonsteroidal anti‐inflammatory drugs (NSAIDs) for acute migraine treatment in a managed care population and its potential impact on functionality.